Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
154 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00910091 | The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer | completed | Phase 2 | 73 | IpsenINDUSTRY | 12 | Jan 30, 2019 | clinicaltrials |
| NCT01435356 | Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy(MAGNOLIA) | terminated | Phase 2 | 83 | European Association of Urology Research FoundationOTHER | 10 | Jan 9, 2019 |
| clinicaltrials |
| NCT01959282 | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | completed | Phase 2 | 219 | Janssen Research & Development, LLCINDUSTRY | 14 | Jan 4, 2019 | clinicaltrials |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 101 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 7 | Dec 19, 2018 | clinicaltrials |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer(NEFERTT) | completed | Phase 2 | 479 | Puma Biotechnology, Inc.INDUSTRY | 35 | Aug 22, 2018 | clinicaltrials |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | completed | Phase 1 / Phase 2 | 110 | Puma Biotechnology, Inc.INDUSTRY | 9 | Jul 26, 2018 | clinicaltrials |
| NCT00527735 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 334 | Bristol-Myers SquibbINDUSTRY | 8 | Jul 18, 2018 | clinicaltrials |
| NCT02596243 | Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E) | unknown | Phase 2 | 134 | Genexine, Inc.INDUSTRY | 3 | Jul 12, 2017 | clinicaltrials |
| NCT01355302 | E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer | terminated | Phase 1 / Phase 2 | 7 | Eisai Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT03113747 | Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds (ADSCs-BWs)(ADSCs-BWs) | unknown | Phase 1 / Phase 2 | 20 | A.A. Partners, LLCOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01493843 | Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | completed | Phase 2 | 501 | Genentech, Inc.INDUSTRY | 16 | Apr 25, 2017 | clinicaltrials |
| NCT01138163 | Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer | completed | Phase 2 | 121 | Peregrine PharmaceuticalsINDUSTRY | 5 | Apr 19, 2017 | clinicaltrials |
| NCT01160601 | Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer | completed | Phase 2 | 86 | Peregrine PharmaceuticalsINDUSTRY | 5 | Apr 19, 2017 | clinicaltrials |
| NCT01272791 | Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer | completed | Phase 2 | 70 | Peregrine PharmaceuticalsINDUSTRY | 2 | Apr 19, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT00102726 | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy | completed | Phase 2 | 183 | GlaxoSmithKlineINDUSTRY | 19 | Mar 23, 2017 | clinicaltrials |
| NCT01457846 | Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer(SHINE) | terminated | Phase 2 | 960 | AstraZenecaINDUSTRY | 16 | Mar 7, 2017 | clinicaltrials |
| NCT02064725 | Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA | unknown | Phase 2 | 8 | Kevelt ASINDUSTRY | 5 | Jan 24, 2017 | clinicaltrials |
| NCT01087151 | A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 118 | Genentech, Inc.INDUSTRY | 12 | Nov 2, 2016 | clinicaltrials |
| NCT00289627 | A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | completed | Phase 2 | 155 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 28, 2016 | clinicaltrials |
| NCT00162123 | A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | completed | Phase 2 | 248 | Bristol-Myers SquibbINDUSTRY | 18 | Jul 27, 2016 | clinicaltrials |
| NCT00079482 | Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) | completed | Phase 2 | 224 | CephalonINDUSTRY | 13 | Jul 21, 2016 | clinicaltrials |
| NCT00674973 | A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 207 | Hoffmann-La RocheINDUSTRY | 19 | Jun 17, 2016 | clinicaltrials |
| NCT02430363 | Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | unknown | Phase 1 / Phase 2 | 58 | Medical Research CouncilOTHER_GOV | 10 | Feb 24, 2016 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT01263886 | Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer(DISRUPT) | completed | Phase 2 | 176 | SanofiINDUSTRY | 13 | Dec 21, 2015 | clinicaltrials |
| NCT01332656 | Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel(OPSALIN) | completed | Phase 2 | 154 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT00768755 | Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 180 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00420888 | ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 526 | Active Biotech ABINDUSTRY | 5 | Jul 22, 2015 | clinicaltrials |
| NCT01500720 | Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer | completed | Phase 2 | 179 | SanofiINDUSTRY | 16 | Apr 13, 2015 | clinicaltrials |
| NCT00865709 | Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects | completed | Phase 2 | 198 | BayerINDUSTRY | 10 | Dec 11, 2014 | clinicaltrials |
| NCT00117637 | BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma | completed | Phase 2 | 189 | BayerINDUSTRY | 7 | Oct 31, 2014 | clinicaltrials |
| NCT00125034 | Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)(OPUS) | completed | Phase 2 | 344 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 13 | Aug 7, 2014 | clinicaltrials |
| NCT01151215 | Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer(MINT) | terminated | Phase 2 | 482 | AstraZenecaINDUSTRY | 18 | Jul 25, 2014 | clinicaltrials |
| NCT01557777 | Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 17 | AbbVie (prior sponsor, Abbott)INDUSTRY | 5 | Jul 4, 2014 | clinicaltrials |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer(FACT) | terminated | Phase 2 / Phase 3 | 80 | Mateon TherapeuticsINDUSTRY | 12 | Jun 9, 2014 | clinicaltrials |
| NCT01124786 | A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) | completed | Phase 2 | 367 | Clovis Oncology, Inc.INDUSTRY | 15 | Apr 17, 2014 | clinicaltrials |
| NCT01561456 | Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung | completed | Phase 2 | 100 | Axelar ABINDUSTRY | 5 | Dec 5, 2013 | clinicaltrials |
| NCT01337154 | First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 140 | CytRxINDUSTRY | 6 | Jun 28, 2013 | clinicaltrials |
| NCT00777309 | A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 167 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 6 | Feb 28, 2013 | clinicaltrials |
| NCT00319254 | Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer | completed | Phase 2 | 75 | PfizerINDUSTRY | 8 | Jan 31, 2013 | clinicaltrials |
| NCT00735904 | Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 38 | PfizerINDUSTRY | 4 | Jan 3, 2013 | clinicaltrials |
| NCT00246571 | Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer | completed | Phase 2 | 217 | PfizerINDUSTRY | 12 | Jul 12, 2012 | clinicaltrials |
| NCT00745875 | ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study | completed | Phase 2 | 66 | AstraZenecaINDUSTRY | 5 | Jun 6, 2012 | clinicaltrials |
| NCT00499265 | Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 95 | Heidelberg Pharma AGINDUSTRY | 6 | Mar 29, 2012 | clinicaltrials |
| NCT00448305 | EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients | completed | Phase 2 | 143 | MediGeneINDUSTRY | 6 | Jan 5, 2012 | clinicaltrials |
| NCT00322348 | Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women | completed | Phase 2 | 98 | AstraZenecaINDUSTRY | 3 | Jan 24, 2011 | clinicaltrials |
| NCT01066494 | A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 20 | Antisoma ResearchINDUSTRY | 2 | Jan 17, 2011 | clinicaltrials |
| NCT00544960 | A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer | completed | Phase 2 | 106 | Ascenta TherapeuticsINDUSTRY | 3 | Aug 27, 2010 | clinicaltrials |
| NCT00397293 | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Ascenta TherapeuticsINDUSTRY | 3 | Aug 24, 2010 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials